Germany’s Respiratory Virus Surge: Record Influenza Cases, Prolonged Outbreaks, and Rising Health Concerns in 2025

Berlin, May 18, 2026 — Germany is experiencing one of its most severe respiratory virus seasons in over a decade, with influenza cases reaching their highest levels in ten years and prolonged outbreaks straining healthcare systems. The 2024/25 influenza season, which ran from autumn to spring, reported 393,998 laboratory-confirmed influenza cases—nearly double the 218,002 cases recorded in the 2023/24 season, according to the latest Robert Koch Institute (RKI) Grippereport. This surge, combined with persistent COVID-19 circulation and rising respiratory syncytial virus (RSV) activity, has left public health officials monitoring the situation closely as Germany transitions into warmer months.

The prolonged nature of the outbreak—spanning 16 weeks, well beyond the typical 8–12 week duration—was driven by the sequential dominance of two influenza strains: Influenza A in the early phase, followed by Influenza B in the latter half of the season. This overlap extended the peak period and increased the risk of co-infections, particularly among vulnerable populations. Meanwhile, influenza-associated mortality also rose sharply, with 1,954 deaths linked to the virus in 2024/25, compared to 1,119 in the previous season. These figures underscore the heightened severity of the season, though experts note that increased testing and reporting since the pandemic may partially explain the higher numbers.

Key Takeaways:

• Record influenza cases: 393,998 lab-confirmed cases in 2024/25—highest in a decade.
• Prolonged outbreak: 16 weeks of elevated activity, driven by two sequential influenza strains.
• Increased mortality: 1,954 influenza-associated deaths in 2024/25, up from 1,119 in 2023/24.
• School-age children hardest hit: Data suggests disproportionate impact on children in primary and secondary education.
• Ongoing respiratory virus risks: COVID-19, RSV, and seasonal flu continue to circulate as Germany enters late spring.

Why Was This Season So Severe?

Public health experts point to several factors contributing to the severity of the 2024/25 respiratory virus season. First, the sequential dominance of Influenza A and B created a prolonged peak, as the two strains circulated almost simultaneously in the latter half of the season. This overlap is unusual and likely contributed to the extended duration of elevated cases. “When two influenza strains are active at the same time, it can lead to more complex outbreaks and higher healthcare demand,” explains Dr. Christian Karagiannidis, a respiratory specialist at the University Hospital of Munich.

Second, reduced population immunity following years of COVID-19 restrictions may have played a role. While vaccination rates for influenza remained steady—around 35–40% of the population, according to the RKI—some groups, particularly the elderly and young children, saw lower uptake. The waning immunity from prior COVID-19 infections may have left some individuals more susceptible to other respiratory viruses.

Third, school-age children were disproportionately affected. The RKI data highlights a notable increase in influenza cases among children aged 5–14, raising questions about transmission dynamics in educational settings. “Children are often the primary drivers of influenza spread, and their return to schools after the holidays can amplify outbreaks,” notes Prof. Maria Söderström, an infectious disease epidemiologist at Charité – Universitätsmedizin Berlin. “This season, the combination of high mobility and lower immunity in this age group likely contributed to the surge.”

COVID-19 and RSV: The Other Players in Germany’s Respiratory Virus Landscape

While influenza dominated headlines, COVID-19 and respiratory syncytial virus (RSV) continued to circulate at elevated levels throughout the season. The RKI’s weekly reports indicate that COVID-19 cases remained above the seasonal baseline, with Omicron subvariants—particularly those with immune-evasive properties—contributing to persistent transmission. As of early May 2025, COVID-19 accounted for approximately 10–15% of all acute respiratory infections reported to sentinel surveillance systems, according to RKI epidemiological bulletins.

RSV, which typically peaks in late autumn and winter, also showed unusually prolonged activity, with cases detected well into the spring. This pattern aligns with observations in other European countries, where RSV outbreaks have extended beyond traditional seasons. “The overlap of RSV, influenza, and COVID-19 creates a ‘triple threat’ scenario for healthcare systems,” warns Dr. Karagiannidis. “Hospitals are already stretched thin, and the simultaneous circulation of these viruses increases the risk of co-infections and severe outcomes, particularly in elderly patients and young children.”

Healthcare System Strain and Public Health Response

The prolonged respiratory virus season has placed significant strain on Germany’s healthcare system. Hospitals in regions with high influenza activity reported increased admissions for pneumonia, bronchiolitis, and other respiratory complications. Pediatric wards, in particular, saw higher occupancy rates, reflecting the disproportionate impact on children. “We’ve had to adjust staffing and resources to manage the influx of cases, especially in intensive care units,” says a spokesperson for the German Hospital Association (DKG), who notes that some facilities had to postpone elective surgeries to prioritize acute respiratory cases.

In response, public health authorities have reiterated vaccination recommendations for the upcoming 2025/26 season. The German Federal Ministry of Health emphasized the importance of annual influenza vaccination, particularly for:

• Individuals aged 60 and older
• Children and adolescents with chronic health conditions
• Healthcare workers and caregivers
• Pregnant women

the RKI has advised enhanced hygiene measures in schools, nursing homes, and healthcare facilities to mitigate transmission. While mask mandates have been lifted in most settings, authorities recommend improved ventilation, hand hygiene, and rapid testing for symptomatic individuals to curb further spread.

What’s Next? Monitoring the Respiratory Virus Landscape

As Germany enters late spring, public health officials are closely monitoring respiratory virus trends to assess whether a summer surge—similar to patterns observed in 2022—may emerge. While influenza activity typically declines in warmer months, COVID-19 and RSV can persist, particularly in indoor settings. The RKI’s next weekly epidemiological report, scheduled for release on May 25, 2026, will provide updated data on virus circulation and hospitalizations.

In the meantime, experts urge the public to remain vigilant. “Even as we move into summer, respiratory viruses can still circulate, especially in crowded or poorly ventilated spaces,” says Prof. Söderström. “Vaccination, solid hygiene, and staying home when sick remain our best tools to protect ourselves and others.”

For the latest updates, readers can consult:

• Robert Koch Institute (RKI) Grippereport
• German Federal Ministry of Health vaccination guidelines
• German Hospital Association (DKG) for healthcare system updates

Expert Perspectives: What This Season Tells Us About Future Outbreaks

Dr. Helena Fischer, Editor of Health at World Today Journal, reflects on the implications of this season’s data: “The 2024/25 respiratory virus season serves as a stark reminder of how quickly and unpredictably these viruses can evolve. The prolonged duration, the sequential strains, and the disproportionate impact on children all highlight gaps in our preparedness. Moving forward, we need to invest in better surveillance, equitable vaccine distribution, and public health strategies that account for the dynamic nature of these pathogens.”

Looking ahead, public health experts are also watching for signs of antiviral resistance, particularly as COVID-19 treatments like Paxlovid face challenges from new variants. “The rapid evolution of these viruses means One can’t afford complacency,” says Dr. Karagiannidis. “Ongoing research into universal vaccines and improved diagnostics will be critical to mitigating future outbreaks.”

Reader Q&A: Common Questions About Germany’s Respiratory Virus Season

Q: Should I still get vaccinated if I already had COVID-19 or the flu this season?
A: Yes. While natural infection provides some immunity, it may not be as broad or long-lasting as vaccination. The flu vaccine, for example, is updated annually to target the most circulating strains, offering better protection against new variants. The RKI recommends vaccination for everyone eligible, regardless of prior infection.

Q: Are there any new treatments for severe respiratory infections?
A: For influenza, antiviral medications like oseltamivir (Tamiflu) remain the standard treatment for high-risk individuals. For COVID-19, options include Paxlovid (nirmatrelvir/ritonavir) and molnupiravir, though resistance to these drugs is being monitored. RSV treatment is largely supportive, though monoclonal antibodies like palivizumab are available for high-risk infants. Research into broad-spectrum antivirals is ongoing.

Q: Will there be another surge this summer?
A: Summer surges are possible, particularly for COVID-19 and RSV, which can persist in indoor environments. However, influenza typically declines in warmer months. The RKI will continue monitoring trends and will update guidance accordingly. Staying informed through official channels is key.

Closing Thoughts: A Call for Vigilance and Preparedness

Germany’s 2024/25 respiratory virus season has underscored the importance of robust public health measures, equitable access to vaccines, and adaptive strategies to address the evolving nature of these pathogens. As the country transitions into summer, the lessons learned from this outbreak will be critical in shaping future responses. Whether through improved surveillance, targeted vaccination campaigns, or enhanced healthcare capacity, the goal remains clear: to protect vulnerable populations and minimize the impact of respiratory viruses on society.

For readers, the message is simple: Stay informed, get vaccinated, and take steps to protect yourself and others. The next chapter in Germany’s respiratory virus story is still being written—and your actions can make a difference.

Have insights or questions about Germany’s health landscape? Share your thoughts in the comments below or reach out to our team for expert analysis.